19,753 Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Purchased by AXQ Capital LP

AXQ Capital LP bought a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 19,753 shares of the company’s stock, valued at approximately $110,000.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of 4D Molecular Therapeutics in the third quarter valued at approximately $295,000. Intech Investment Management LLC acquired a new position in shares of 4D Molecular Therapeutics in the third quarter worth $268,000. Algert Global LLC increased its position in shares of 4D Molecular Therapeutics by 342.7% during the third quarter. Algert Global LLC now owns 73,436 shares of the company’s stock worth $794,000 after acquiring an additional 56,848 shares during the period. Walleye Capital LLC acquired a new stake in shares of 4D Molecular Therapeutics in the third quarter valued at $912,000. Finally, Braidwell LP raised its stake in shares of 4D Molecular Therapeutics by 231.7% in the third quarter. Braidwell LP now owns 1,225,448 shares of the company’s stock valued at $13,247,000 after acquiring an additional 855,990 shares in the last quarter. 99.27% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have weighed in on FDMT. Bank of America cut their price target on 4D Molecular Therapeutics from $42.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, March 10th. Chardan Capital reduced their target price on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and set a $36.00 price target on shares of 4D Molecular Therapeutics in a report on Monday, March 3rd. Royal Bank of Canada dropped their price objective on shares of 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a research report on Monday, March 3rd. Finally, BMO Capital Markets cut shares of 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $30.63.

4D Molecular Therapeutics Price Performance

Shares of FDMT opened at $3.93 on Tuesday. The firm has a fifty day moving average price of $4.68 and a 200 day moving average price of $7.30. The stock has a market cap of $181.97 million, a PE ratio of -1.38 and a beta of 2.83. 4D Molecular Therapeutics, Inc. has a 1-year low of $3.58 and a 1-year high of $36.25.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.10). As a group, equities analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.